SP600125 is a selective, ATP-competitive JNK inhibitor. SP600125 reversibly inhibits JNK1, 2 and 3 (IC50 = 40 - 90 nM) with negligible activity at ERK2, p38β and a range of enzymes (IC50 > 10 μM). SP600125 potently decreased renal epithelial tubular cell apoptosis induced by renal ischemia/reperfusion via suppression of the extrinsic pathway. In cells, SP600125 dose dependently inhibited the phosphorylation of c-Jun, the expression of inflammatory genes COX-2, IL-2, IFN-gamma, TNF-alpha, and prevented the activation and differentiation of primary human CD4 cell cultures. In mice, SP600125 (15 mg/kg or 30 mg/kg) blocked lipopolysaccharide (LPS)-induced TNF-α expression and anti-CD3-induced apoptosis of CD4(+) CD8(+) thymocytes.
Drug Des Devel Ther. 2019 Aug 12;13:2787-2798.
Cell Mol Neurobiol. 2019 Mar;39(2):301-319.
Myosin IIA Regulated Tight Junction in Oxygen Glucose-Deprived Brain Endothelial Cells Via Activation of TLR4/PI3K/Akt/JNK1/2/14-3-3ε/NF-κB/MMP9 Signal Transduction Pathway.
SP600125 purchased from AbMole
Mol Cells. 2017 May 31;40(5):363-370.
|Source||Molecules and Cells (2017). Figure 5. SP600125 (Abmole Bioscience, USA)|
|Method||Wound healing assay|
|Cell Lines||EGI-1 cells|
|Results||The JNK inhibitor significantly decreased cell migration and invasion, as well as JNK phosphorylation (Figs. 5A-5C), but not cell proliferation (Fig. 5D).|
|Cell lines||A549 cells|
|Preparation method||Cell viability assay.
Cell viability was evaluated using the Cell Counting kit (CCK)-8 assay (AbMole). In brief, the cells were seeded into 96-well plates at a density of 3×103 cells/well and left to adhere overnight. The cells were then incubated with or without 0–40 nM SP600125. Then, 100 μl CCK-8 was added and incubated in the dark at 37°C for 3 h. The absorbance was determined using the MRX II microplate reader (Dynex, Chantilly, VA, USA) at a wavelength of 450 nm.
|Incubation time||24 h|
|Animal models||Female CD-1 mice|
|Formulation||30% PEG-400/20% polypropylene glycol/15% Cremophor EL/5% ethanol/30% saline|
|Dosages||0, 12, 24, and 36 h, 15 mg/kg|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO 40 mg/mL|
JNK inhibitor SP600125 protects against lipopolysaccharide-induced acute lung injury via upregulation of claudin-4.
Zheng Y, et al. Exp Ther Med. 2014 Jul;8(1):153-158. PMID: 24944614.
SP600125, a selective JNK inhibitor, protects ischemic renal injury via suppressing the extrinsic pathways of apoptosis.
Wang Y, et al. Life Sci. 2007 May 8;80(22):2067-75. PMID: 17459422.
SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase.
Bennett BL, et al. Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13681-6. PMID: 11717429.
|Related JNK Products|
Tanzisertib (CC-930) is a potent JNK1/2/3 inhibitor with IC50s of 61/7/6 nM, respectively.
DTP3 is a selective GADD45β/MKK7 inhibitor, which inhibits cancer-selective NF-κB survival pathway.
Vacquinol-1 is an MKK4 activator, which rapidly and selectively induces glioma cell death.
IQ-1S is a potent and selective JNK inhibitor with Kds of 100 nM, 240 nM, and 360 nM for JNK3, JNK1, and JNK2, respectively.
Bentamapimod, also known as AS602801, is an ATP-competitive JNK inhibitor with IC50 of 80 nM, 90 nM, and 230 nM for JNK1, JNK2, and JNK3, respectively.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.